Work

Rabbit ATLG and thymoglobulin in haploidentical hematopoietic cell transplantation product specific evidence and unresolved dosing with PTCy

Year: 2026
Type: article
Abstract: Rabbit anti-T-lymphocyte globulin (ATLG; Grafalon) and rabbit anti-thymocyte globulin (ATG; Thymoglobulin) are noninterchangeable polyclonal preparations used within haploidentical hematopoietic cell transplantation (haplo-HCT) platforms. Their immunogens, antibody repertoires and nominal dose scales differ, but direct comparative clinical evidence is sparse. This narrative review examines product-specific evidence, active-antibody exposure and the unresolved dosing of serotherapy combined with post-transplant cyclophosphamide (PTCy). The available propensity-matched haploidentical comparison used Thymoglobulin 6 mg/kg and ATLG 10 mg/kg; the latter was substantially below ATLG totals commonly used even in matched-donor transplantation. Its infection and chronic graft-versus-host disease findings therefore cannot establish intrinsic product differences. PTCy-based and serotherapy-based platforms coexist, including outside Western centers, and neither the optimal rabbit-globulin dose nor the optimal PTCy dose in combined regimens is established. Recipient absolute lymphocyte count (ALC), infusion timing and graft cellularity modify exposure. ATLG-specific ALC studies support this association, but prospectively validated ATLG ALC-based dosing models remain needed. Product, conditioning, graft source, PTCy, mycophenolate mofetil and other immunosuppression should be evaluated as one protocol. Clinical use should follow product-specific, locally validated regimens while trials define exposure targets and the net benefit of combination prophylaxis.
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $4,790
OpenAlex ID: W7233801990
FWCI:
Cites:
Cited by:
Related to: 10